Peginterferon alfa-2a [Pegylated Interferon alfa-2a]
Generic Details
Generic Name
Peginterferon Alfa-2a (Pegylated Interferon Alfa-2a)
Other Names
- Pegasys
Drug Class
- Antiviral
- Immunomodulator
Chemical Formula
C860H1406N226O251S9
Molecular Weight
19.087 kDa
Mechanism of Action
- Stimulates immune system to fight viral infections
Indications
- Chronic Hepatitis B
- Chronic Hepatitis C
Common Dosage Forms
- Prefilled syringe
- Solution for injection
Typical Dosage
- 180 mcg once weekly for Hepatitis C
- 135-180 mcg once weekly for Hepatitis B
Pediatric Dosage
- Safety and efficacy not established in children
Geriatric Dosage
- Dosage adjustment may be needed in elderly patients
Side Effects
- Fatigue
- Headache
- Nausea
- Insomnia
- Injection site reactions
- Flu-like symptoms
Contraindications
- Hypersensitivity to Peginterferon Alfa-2a
- Autoimmune hepatitis
- Severe psychiatric disorders
Pregnancy Category
- Category C - Risk cannot be ruled out
Lactation Safety
- Caution advised. Limited data available.
Drug Interactions
- Ribavirin
- Didanosine
- Theophylline
- Methadone
Overdose Symptoms
- Severe fatigue
- Severe headache
- Severe dizziness
Antidote for Overdose
- No specific antidote. Supportive care
Storage Conditions
- Refrigerate at 2-8°C. Do not freeze.
Pharmacokinetics
- Absorption: Slow and prolonged
- Distribution: Distributed into systemic circulation
- Metabolism: Hepatic metabolism
- Excretion: Primarily renal excretion
Precautions
- Monitor blood counts
- Monitor liver function tests
- Monitor for psychiatric symptoms
Warnings
- Risk of depression and suicidal ideation
- Hepatic decompensation in patients with cirrhosis
Others
- Regular monitoring is essential during treatment.